Opioid Analgesics and Antagonists

Classification

Strong agonists: morphine, fentanyl, methadone, oxycodone, hydromorphone. Moderate/weak: codeine, tramadol(dual mechanism). Partial agonist: buprenorphine. Mixed agonist-antagonist: pentazocine, nalbuphine, butorphanol. Antagonists: naloxone, naltrexone, methylnaltrexone(peripherally restricted).

Mechanism

μ/κ/δ GPCRs(central: PAG, dorsal horn; peripheral to lesser extent) → open K+ channels + close voltage-gated Ca2+ channels → hyperpolarize, ↓neurotransmitter(substance P) release at dorsal horn → blunts nociception at MULTIPLE pain-pathway points. μ receptor = responsible for BOTH most analgesia AND most major adverse effects(resp depression, euphoria/dependence, constipation, miosis) — SAME receptor, benefit+harm inseparable with pure agonist → motivates alternative-profile agents.

Buprenorphine(partial agonist): HIGH affinity, LOW intrinsic activity at μ → CEILING EFFECT on analgesia+resp depression(↑dose beyond point = no proportional ↑effect) → safer OD profile than full agonists → basis for opioid dependence Rx(high-affinity occupancy blocks full agonists like heroin, enough intrinsic activity prevents withdrawal, self-limiting max). HIGH affinity → CAN PRECIPITATE WITHDRAWAL if given to patient on full agonist(displaces full agonist, provides LESS net intrinsic activity) → induction requires patient already in MILD withdrawal first.

Pentazocine(mixed agonist-antagonist): κ AGONIST, μ ANTAGONIST/weak partial agonist — analgesia via κ. Same displacement logic → can precipitate withdrawal in full-agonist patient(at μ specifically). κ-mediated: dysphoria, hallucinations(distinct from pure μ agonists).

Tramadol: DUAL mechanism — weak μ agonism + 5-HT/NA reuptake inhibition(independent non-opioid analgesic component, descending inhibitory pathways) → BOTH opioid-class seizure/dependence risk AND serotonin syndrome risk(+SSRIs/MAOIs) — combination not seen with pure opioid agonists.

Naloxone/naltrexone: competitive antagonists ALL opioid receptors, negligible intrinsic activity, reverse by displacement. Naloxone SHORT t½ vs most full agonists(esp long-acting methadone) → single dose can wear off BEFORE causative opioid does → RENARCOTIZATION/re-sedation after apparent reversal → needs monitoring+repeat dosing/infusion, NOT single-dose-cures-all assumption.

Adverse Effects

Respiratory depression: DOMINANT dangerous acute effect — μ action on brainstem resp centres ↓CO2 responsiveness. Proximate cause of OD death; specifically reversed by naloxone.

Constipation: μ receptors in enteric NS ↓GI motility. NO TOLERANCE develops(unlike analgesic/sedative/resp-depressant effects which DO develop tolerance relatively fast) → chronic opioid therapy needs ONGOING PROACTIVE laxative co-prescription, not “it’ll resolve” expectation — high-yield BECAUSE tolerance to analgesia(needing dose escalation) makes this differential lack of tolerance easy to overlook.

Miosis: also NO significant tolerance → useful sign of intoxication/OD even in tolerant chronic user. Classic OD triad: pinpoint pupils + resp depression + depressed consciousness.

Tolerance & physical dependence: develop to analgesic/euphoric/sedative/resp-depressant effects(different rates each) via receptor downregulation/desensitization. DISTINCT from addiction(behavioural, compulsive use despite harm) and from pseudo-addiction(drug-seeking from genuinely UNDERTREATED pain, resolves once pain controlled) — conflating these 3 = common exam error, esp. re: appropriate opioid use in pain management vs recognizing true addiction.

Withdrawal syndrome: physiological rebound from removed chronic μ-inhibition — autonomic hyperactivity(lacrimation, rhinorrhoea, sweating, piloerection, diarrhoea), dysphoria, myalgia. Unpleasant/distressing but NOT typically life-threatening(unlike alcohol/benzodiazepine withdrawal) — specific contrast point across subject.

Clinical Relevance

μ receptor’s DUAL responsibility(analgesia + most adverse effects) = organizing fact: explains why buprenorphine’s ceiling(on BOTH effects together) = safer not just “weaker”; why mixing full agonist+partial/mixed agonist-antagonist precipitates withdrawal via simple receptor-occupancy displacement; why managing opioid-dependent chronic pain requires distinguishing genuine tolerance/physical dependence(expected pharmacology) from addiction(separate behavioural diagnosis) rather than treating dose escalation/withdrawal-avoidance as automatic proof of the latter.

Classification

Strong agonists: morphine, fentanyl, methadone, oxycodone, hydromorphone
Moderate/weak agonists: codeine, tramadol (also a monoamine reuptake inhibitor — dual mechanism)
Partial agonists: buprenorphine
Mixed agonist-antagonists: pentazocine, nalbuphine, butorphanol
Antagonists: naloxone, naltrexone, methylnaltrexone (peripherally restricted)

Mechanism of Action

Opioids act on μ (mu), κ (kappa), and δ (delta) G-protein-coupled receptors, distributed both centrally (periaqueductal grey, dorsal horn of the spinal cord, and elsewhere) and, to a lesser extent, peripherally — receptor activation opens K⁺ channels and closes voltage-gated Ca²⁺ channels, hyperpolarizing neurons and reducing neurotransmitter (including substance P) release at the dorsal horn, blunting nociceptive signal transmission at multiple points along the pain pathway rather than a single site. The μ receptor is responsible for most of both morphine’s analgesic effect and its major adverse effects (respiratory depression, euphoria/dependence potential, constipation, miosis) — this single-receptor explanation for both benefit and the majority of the harm is the central organizing fact of the whole topic, since it means analgesia and the dangerous/limiting adverse effects cannot be easily separated with a pure μ agonist, motivating the alternative receptor-profile agents below.

Partial agonists (buprenorphine): high affinity but low intrinsic activity at the μ receptor — produces a ceiling effect on both analgesia and respiratory depression (increasing the dose beyond a certain point does not proportionally increase either effect, unlike a full agonist), giving buprenorphine a substantially safer overdose profile than full agonists, the pharmacological basis for its use in opioid dependence treatment (occupies the receptor with high affinity, blocking full agonists like heroin from binding, while providing enough intrinsic activity to prevent withdrawal, at a self-limiting maximum effect). Its high receptor affinity, however, means it can precipitate withdrawal if given to a patient already using a full agonist (displaces the full agonist from the receptor but provides less net intrinsic activity than the full agonist was providing) — the reason buprenorphine induction requires the patient to already be in mild withdrawal before starting, not simply substituted at any point.

Mixed agonist-antagonists (pentazocine): agonist at κ receptors, antagonist (or weak partial agonist) at μ receptors — analgesic via the κ pathway, but this receptor profile means giving pentazocine to a patient on a full μ agonist can precipitate withdrawal (same displacement logic as buprenorphine, at the μ receptor specifically), and κ-mediated effects bring a distinct adverse-effect profile (dysphoria, hallucinations) not shared with pure μ agonists.

Tramadol: a genuinely dual mechanism — weak μ agonism plus inhibition of serotonin and noradrenaline reuptake (contributing an independent, non-opioid analgesic component via descending inhibitory pain pathways) — this dual mechanism is also the reason tramadol carries both an opioid-class seizure/dependence risk profile and a serotonin syndrome risk when combined with other serotonergic drugs (SSRIs, MAOIs), a combination of liabilities not seen with pure opioid agonists.

Naloxone/naltrexone: competitive antagonists at all opioid receptors with negligible intrinsic activity, reversing agonist effects by displacement. Naloxone’s short half-life relative to most full agonists (particularly long-acting ones like methadone) is a specific, high-yield clinical point — a single naloxone dose can wear off before the causative opioid does, producing re-sedation/renarcotization after apparent initial reversal, which is why opioid overdose management requires close monitoring and often repeated dosing or an infusion, not a single dose assumed to be curative.

Adverse Effects

Respiratory depression: the dominant, most dangerous acute effect, mediated by μ receptor action on the brainstem respiratory centres reducing their responsiveness to CO2 — the proximate cause of death in opioid overdose, and the effect naloxone specifically reverses.

Constipation: mediated by μ receptors in the enteric nervous system, reducing GI motility — unlike most other opioid adverse effects, tolerance does not develop to opioid-induced constipation with continued use (in contrast to tolerance developing relatively quickly to the analgesic, sedative, and respiratory-depressant effects), meaning a patient on chronic opioid therapy needs ongoing, proactive laxative co-prescription rather than an expectation that this side effect will resolve with time — a specific, frequently tested point precisely because tolerance to the analgesic effect (requiring dose escalation over time) makes this differential lack of tolerance to constipation clinically significant and easy to overlook.

Miosis (pinpoint pupils): also does not show significant tolerance, remaining a useful clinical sign of opioid intoxication/overdose even in a tolerant chronic user — the combination of pinpoint pupils, respiratory depression, and depressed consciousness is the classic opioid overdose triad.

Tolerance and physical dependence: develop with chronic use to the analgesic, euphoric, sedative, and respiratory-depressant effects (each at a somewhat different rate) via receptor downregulation/desensitization mechanisms — physical dependence (a physiological adaptation producing a withdrawal syndrome on cessation) is distinct from addiction (a behavioural syndrome of compulsive use despite harm) and from pseudo-addiction (drug-seeking behaviour from genuinely undertreated pain, which resolves once pain is adequately controlled) — conflating these three concepts is a common, specifically-examined error, particularly relevant to appropriate opioid use in genuine pain management versus recognizing true addiction.

Opioid withdrawal syndrome: the physiological rebound from chronic μ-receptor-mediated inhibition being removed — autonomic hyperactivity (lacrimation, rhinorrhoea, sweating, piloerection, diarrhoea), dysphoria, and generalized pain/myalgia, generally unpleasant and distressing but, unlike alcohol/benzodiazepine withdrawal, not typically life-threatening on its own (a specific, examined contrast between the different withdrawal syndromes covered across this subject).

Clinical Relevance

The μ receptor’s dual responsibility for both morphine’s analgesic benefit and most of its dangerous adverse effects is the single fact this whole topic is organized around: it explains why buprenorphine’s partial agonism (ceiling on both effects together) makes it safer rather than simply “weaker,” why mixing a full agonist with a partial agonist or mixed agonist-antagonist can precipitate withdrawal through simple receptor-occupancy displacement, and why managing opioid-dependent chronic pain requires distinguishing genuine tolerance/physical dependence (expected, manageable pharmacology) from addiction (a separate behavioural diagnosis) rather than treating any dose escalation or withdrawal-avoidance behaviour as proof of the latter.

Dose-response curves for full agonist vs partial agonist (buprenorphine) showing the ceiling effect on analgesia and respiratory depression.
μ receptor’s dual role diagram: same receptor activation branching to both analgesia and each major adverse effect.
Naloxone vs long-acting opioid half-life comparison explaining renarcotization risk.